Lansoprazole and Esomeprazole in Symptomatic GERD
- 124 Downloads
To evaluate the onset and degree of symptom relief in a population of patients with symptomatic gastro-oesophageal reflux disease (GERD) treated with lansoprazole 30mg or esomeprazole 40mg, each administered once daily.
This was a phase IIIb, prospective, randomised, double-blind, active-controlled, multicentre study of patients with a history of symptomatic GERD.
Patients with symptomatic GERD based on preset criteria were randomised in a 1: 1 ratio to lansoprazole or esomeprazole for 2 weeks. Efficacy endpoints were the percentage of patients without daytime heartburn after the first treatment day, the percentage of patients without night-time heartburn after the first treatment day, and symptom relief (measured as percentage of days and nights without heartburn) and average symptom severity after the first day, during the first 3 days (primary efficacy endpoint), during the first week and during the 2-week treatment period.
3034 patients were randomised to lansoprazole 30mg (n = 1520) or esomeprazole 40mg (n = 1514). Patients in both treatment groups reported increases from baseline in the percentages of days and nights without heartburn and decreases in the average daytime and night-time heartburn severity during the 2-week treatment period. No statistically significant differences were observed between the lansoprazole 30mg and esomeprazole 40mg treatment groups in heartburn relief parameters on day 1 or during the first 3 days, the first week or the 2-week treatment period after adjusting for differences in baseline heartburn severity. Both treatments were well tolerated. Significantly higher percentages of patients treated with esomeprazole as compared with those treated with lansoprazole reported treatment-emergent dry mouth (0.5% vs 0.1 %, p = 0.021) and vomiting (0.5% vs 0.1%, p = 0.038). The most common treatment-related adverse events were diarrhoea (lansoprazole 1.4%, esomeprazole 1.8%), flatulence (lansoprazole 0.7%, esomeprazole 1.0%) and abdominal pain (lansoprazole 1.1%, esomeprazole 1.3%).
Lansoprazole 30mg once daily or esomeprazole 40mg once daily for 2 weeks effectively increase the percentage of days and nights patients with symptomatic GERD are without heartburn and reduce the average severity of daytime and night-time heartburn.
This research was supported by a grant from TAP Pharmaceutical Products Inc., Lake Forest, Illinois, USA.
We wish to thank the participating investigators (see Appendix) for their contribution to the study, and TAP Pharmaceutical Products Inc., Lake Forest, Illinois, USA for their support.
- 2.Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treatment with newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998–1017PubMedCrossRefGoogle Scholar
- 15.Dohmen W, Fuchs W, Seelis REA. Onset and duration of pain relief in gastro-esophageal reflux disease (GERD): a clinical comparison of lansoprazole, omeprazole MUPS and esomeprazole [abstract]. Gastroenterology 2002; 122 Suppl. 1: A201Google Scholar
- 16.Vakil NB, Zuckerman S, Levine JG. Nocturnal heartburn in patients with erosive esophagitis and its resolution with proton pump inhibitors [abstract]. Gastroenterology 2002; 122 Suppl. 1: A200Google Scholar
- 18.van Eiteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Statis Inst 1960; 37: 351–61Google Scholar
- 20.The Gallup Organization. A Gallup Organization National Survey: Understanding heartburn in America. Princeton, NJ: The Gallup Organization. May 2000Google Scholar